Intercept Pharmaceuticals Inc

Seite 1 von 5
neuester Beitrag: 27.05.20 08:32
eröffnet am: 09.01.14 14:25 von: rokrockt Anzahl Beiträge: 117
neuester Beitrag: 27.05.20 08:32 von: moggemeis Leser gesamt: 27654
davon Heute: 6
bewertet mit 7 Sternen

Seite: 1 | 2 | 3 | 4 | 5 | 5   

09.01.14 14:25

5696 Postings, 2751 Tage rokrocktIntercept Pharmaceuticals Inc

Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significa...

ntercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced that the FLINT trial of obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis (NASH) has been stopped early for efficacy based on a planned interim analysis showing that the primary endpoint of the trial has been met. FLINT is a multi-center, double-blind, placebo-controlled clinical trial assessing the safety and efficacy of a 25 mg oral dose of OCA administered daily to biopsy-proven adult NASH patients over a 72-week treatment period. The trial has been sponsored and conducted by the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), a part of the National Institutes of Health, at eight leading US academic hepatology centers comprising the NIDDK's NASH clinical research network (CRN).

The decision to stop FLINT has been based on the recommendation of the Data Safety Monitoring Board (DSMB) which reviewed liver biopsy data from before and at the end of the treatment period in approximately half of the 283 randomized patients, in accordance with a planned interim efficacy analysis. This analysis demonstrated that OCA treatment resulted in a highly statistically significant improvement (p=0.0024 on an intention-to-treat [ITT] basis) in the primary histological endpoint, defined as a decrease in the NAFLD Activity Score (NAS) of at least two points with no worsening of fibrosis, as compared to placebo. Those patients who had not yet completed the trial and therefore did not have a second biopsy were treated as non-responders in the ITT analysis. The pre-defined threshold of statistical significance for stopping FLINT was p < 0.0031.

"The unexpected early stopping of FLINT due to OCA meeting the primary endpoint with such high significance is a major milestone," said Mark Pruzanski, M.D., Chief Executive Officer of Intercept. "NASH has grown to epidemic proportions worldwide, having become a leading cause of cirrhosis and liver failure. On its current trajectory, the disease is projected to become the leading indication for liver transplant. We are deeply grateful to the NIDDK and the NASH CRN for their longstanding commitment both to improving our understanding of the disease and to sponsoring ambitious trials like FLINT in their quest to identify novel treatments for patients suffering from NASH."

Intercept will discuss NASH and the FLINT trial during the previously announced conference call and audio webcast scheduled to take place today at 4:30 p.m. ET. The live event will be available on the investor page of the Intercept website at or by calling (855) 232-3919 (domestic) or (315) 625-6894 (international) five minutes prior to the start time. A replay of the call will be available on the Intercept website approximately two hours after the completion of the call and will be archived for two weeks  
Seite: 1 | 2 | 3 | 4 | 5 | 5   
91 Postings ausgeblendet.

09.08.18 20:09

186 Postings, 1131 Tage shark23sehr stabil nach diesem up

da sind wohl noch viele Käufer nicht drinnen...  

11.09.18 16:21

186 Postings, 1131 Tage shark23wie am schnürl

26.09.18 16:52

186 Postings, 1131 Tage shark23Ich

07.01.19 23:51

186 Postings, 1131 Tage shark23Intercept international

Nicht mal die Firma richtig geschrieben die Holzköpfe von Analysten  

19.02.19 16:38

5461 Postings, 1082 Tage VassagoICPT 124,69$ (+13%)

01.03.19 12:04

5461 Postings, 1082 Tage VassagoICPT 99,74$

Intercept meldet Zahlen für 2018

  • Umsatz 180 Mio. $ (vgl. 131)
    • 2019-er Umsatzprognose 225-240 Mio. $
  • Verlust 309 Mio. $ (vgl. 360)
  • Cash 436 Mio. $
  • Equity 19 Mio. $


11.04.19 16:27

5461 Postings, 1082 Tage VassagoICPT 106,65$ (-12%)

Ich lese die Überschrift "Additional Positive Data From NASH Study" und sehe die Kursreaktion und denke mir dann so...ok...  

11.04.19 23:19

186 Postings, 1131 Tage shark23Sell on good news...

09.05.19 15:35

5461 Postings, 1082 Tage VassagoICPT 82,32$ (-6%)

Intercept plant Finanzierung

  • 200 Mio. $ durch eine Kapitalerhöhung
  • 200 Mio. $ convertible senior notes due 2026


07.06.19 16:21

5461 Postings, 1082 Tage VassagoICPT 76,00$ (-5%)

Das 52 Wochen-Tief liegt bei 71,16$.  

02.08.19 17:18

5461 Postings, 1082 Tage VassagoICPT 61,70$

  • neues 52 Wochen-Tief
  • Zahlen für Q2/19 am 07. August

26.11.19 22:15

186 Postings, 1131 Tage shark23Der Zug nimmt Fahrt auf. 200 Euro bis Weihnachten

26.02.20 10:47

5461 Postings, 1082 Tage VassagoICPT 84,68$

Zahlen für 2019

  • Umsatz 252 Mio. $ (VJ 180)
  • Verlust 345 Mio. $ (VJ 309)
  • Cash 657 Mio. $
  • MK 2,77 Mrd. $

"The FDA has set a Prescription Drug User Fee Act(?PDUFA?) target action date of June 26, 2020for the completion of its review of our NDA seeking approval of OCA for liver fibrosis due to NASH.  As a result of the uncertainties relating to the launch of OCA in liver fibrosis due to NASH and their potential impact on our 2020 financial performance, we are not providing 2020 net sales guidance."


19.03.20 09:43

5461 Postings, 1082 Tage VassagoICPT 48.34$ (-14%)

  • MK 1,59 Mrd. $
  • neues 52 WT
  • kurz- bis mittelfristige Katalysatoren

12.05.20 13:52

186 Postings, 1131 Tage shark23genfit schon mal weg...

22.05.20 14:18

636 Postings, 1261 Tage Ice-Nine comingVerzögerungen AdCom und PDUFA

Scheint heute nicht mein Tag zu sein. Eben erst AMRN und nun hier auch. Unerwartet und unschön, aber aufgeschoben ist ja bekanntlich nicht aufgehoben. Hoffe ich mal.... ;-)))

NEW YORK, May 22, 2020 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that based on discussions earlier this week, the U.S. Food and Drug Administration (FDA) has notified Intercept that its tentatively scheduled June 9, 2020 advisory committee meeting (AdCom) relating to the company?s new drug application (NDA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH) has been postponed. The postponement will accommodate the review of additional data requested by the FDA that the company intends to submit within the next week. The FDA has indicated that it will reach out to Intercept in the near future with a new proposed AdCom date. Intercept now anticipates that the FDA?s review of its NDA will extend beyond the Prescription Drug User Fee Act (PDUFA) target action date of June 26, 2020.

22.05.20 16:32

5461 Postings, 1082 Tage VassagoICPT 78.23$ (-15%)

Sitzung des Beratungsausschusses wird verschoben

Die FDA hat zusätzliche Daten angefordert.


22.05.20 16:44

636 Postings, 1261 Tage Ice-Nine comingre #114

Danke für die "Übersetzung" .... ;-))))  

Seite: 1 | 2 | 3 | 4 | 5 | 5   
   Antwort einfügen - nach oben

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Deutsche Bank AG514000
Wirecard AG747206
Scout24 AGA12DM8
Lufthansa AG823212
Daimler AG710000
Airbus SE (ex EADS)938914
BioNTech SE (spons. ADRs)A2PSR2
ITM Power plcA0B57L
Carnival Corp & plc paired120100
Shell (Royal Dutch Shell) (A)A0D94M